IsoRay receives approval to market cancer therapy in Canada

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced that Health Canada’s Therapeutic Products Directorate has approved IsoRay’s Proxcelan Cs-131 brachytherapy seeds for sale throughout Canada.

In a press release, IsoRay CEO Dwight Babcock stated, “This completes another step in being able to expand the potential distribution of cesium-131 brachytherapy seeds. We initially plan to leverage the relationships of our exclusive U.S. distributor, BrachySciences, and contacts we have made with Canadian physicians who are interested in using cesium-131 to treat their patients. Through these channels we hope to begin to penetrate the Canadian brachytherapy market.”

Related external links (will open a new window):

  • Read the IsoRay press release

    Related WTC links:

  • IsoRay is a WTC client
  • – end of post –

    Advertisements
    This entry was posted in Company_and_Client_News, IsoRay, Life_Sciences. Bookmark the permalink.

    Leave a Reply

    Fill in your details below or click an icon to log in:

    WordPress.com Logo

    You are commenting using your WordPress.com account. Log Out /  Change )

    Google photo

    You are commenting using your Google account. Log Out /  Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out /  Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out /  Change )

    Connecting to %s